Purchase this article with an account.
Antoinette C. Lambooij, Robert W. A. M. Kuijpers, Elgin G. R. van Lichtenauer–Kaligis, Mike Kliffen, G. Seerp Baarsma, P. Martin van Hagen, Cornelia M. Mooy; Somatostatin Receptor 2A Expression in Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2000;41(8):2329-2335.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. The growth of ocular neovascularization is regulated by a balance
between stimulating and inhibiting growth factors. Somatostatin affects
angiogenesis by inhibiting the growth hormone–insulin-like growth
factor axis and also has a direct antiproliferative effect on human
retinal endothelial cells. The purpose of our study is to investigate
the expression of somatostatin receptor (sst) subtypes and particularly
sst subtype 2A (sst2A) in normal human macula, and to study
sst2A in different stages of age-related maculopathy (ARM),
because of the potential anti-angiogenic effect of somatostatin
methods. Sixteen eyes (10 enucleated eyes, 4 donor eyes, and 2 surgically
removed choroidal neovascular [CNV] membranes) of 15 patients with
eyes at different stages of ARM were used for immunohistochemistry.
Formaldehyde-fixed paraffin-embedded slides were incubated with a
polyclonal anti-human sst2A antibody. mRNA expression of
five ssts and somatostatin was determined in the posterior pole of
three normal human eyes by reverse transcriptase–polymerase chain
results. The immunohistochemical expression of sst2A in newly formed
endothelial cells and fibroblast-like cells was strong in fibrovascular
CNV membranes. mRNA of sst subtypes 1, 2A, and 3, as well as
somatostatin, was present in the normal posterior pole; sst subtypes 4
and 5 were not detectable.
conclusions. Most early-formed CNV in ARM express sst2A. The presence of
mRNA of sst subtype 2A was observed in normal human macula, and
subtypes 1 and 3 and somatostatin are also present. sst2A receptors bind potential anti-angiogenic somatostatin analogues such as
octreotide. Therefore, somatostatin analogues may be an effective
therapy in early stages of CNV in ARM.
This PDF is available to Subscribers Only